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Abstract: Premedication with a combination of histamine H1 receptor (H1R) and H2 
receptor (H2R) antagonists has been suggested as a prophylactic principle, for instance, in 
anaesthesia and surgery. Aiming at pharmacological hybrids combining H1R and H2R 
antagonistic activity, a series of cyanoguanidines 14–35 was synthesized by linking 
mepyramine-type H1R antagonist substructures with roxatidine-, tiotidine-, or  
ranitidine-type H2R antagonist moieties. N-desmethylmepyramine was connected via a 
poly-methylene spacer to a cyanoguanidine group as the “urea equivalent” of the H2R 
antagonist moiety. The title compounds were screened for histamine antagonistic activity 
at the isolated ileum (H1R) and the isolated spontaneously beating right atrium (H2R) of the 
guinea pig. The results indicate that, depending on the nature of the H2R antagonist partial 
structure, the highest H1R antagonist potency resided in roxatidine-type compounds with 
spacers of six methylene groups in length (compound 21), and tiotidine-type compounds 
irrespective of the alkyl chain length (compounds 28, 32, 33), N-cyano-N'-[2-[[(2-
guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridyl)-amino] 
ethyl]-N-methylamino]ethyl] guanidine (25, pKB values: 8.05 (H1R, ileum) and 7.73 (H2R, 
atrium) and the homologue with the mepyramine moiety connected by a six-membered 
chain to the tiotidine-like partial structure (compound 32, pKB values: 8.61 (H1R) and 6.61 
(H2R) were among the most potent hybrid compounds. With respect to the development of a 
potential pharmacotherapeutic agent, structural optimization seems possible through selection 
of other H1R and H2R pharmacophoric moieties with mutually affinity-enhancing properties. 
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1. Introduction 
The biogenic amine histamine mediates its effects via four histamine receptor subtypes, termed H1, 
H2, H3, and H4 receptors (HxR) [1–3]. The histamine receptors belong to class A of the superfamily of 
G-protein-coupled receptors (GPCRs). As an autacoid and neurotransmitter, histamine is involved in 
numerous physiological and pathophysiological processes. Antagonists of the H3R [4] and the most 
recently discovered H4R [5] are still under investigation as potential drugs, e.g., for the treatment of 
CNS disorders and inflammatory diseases, respectively [6]. By contrast, H1R and H2R antagonists are 
well established therapeutic agents for decades. Numerous pathophysiological responses to histamine 
released from mast cells and basophils through immunological or non-immunological mechanisms are 
mediated by the H1R, for instance, vasodilatation via nitric oxide release, increase in capillary 
permeability, contraction of smooth muscles, e.g., in gut and bronchi. The first H1R blockers [7] have 
been described as “antihistamines” more than 70 years ago, and especially the newer non-sedating H1R 
antagonists are widely used in the treatment of allergic conditions [7]. Stimulation of gastric acid 
secretion is the most prominent physiological effect of H2R stimulation. In the 1970s the development 
of the H2R antagonists revolutionized the treatment of gastric and duodenal ulcers [8]. Histamine can 
also induce cardiovascular effects via H2Rs, e.g., increase in heart rate and cardiac contractility as well 
as vasodilatation [9]. 
The combined administration of H1R and H2R antagonists has been suggested, for example, as a 
prophylactic principle in anaesthesia, for the prevention of hypersensitivity reactions to drugs, e.g., in 
cancer chemotherapy, or for the treatment of skin diseases [10–15]. Histamine release during 
anaesthesia and surgery is still a widely known problem in clinical practice [10]. The ratio of 
anaphylactic/anaphylactoid reaction incidents is about 20%–30%, and life threatening reactions are 
observed in 0.1%–0.5% of all cases [16]. Cardiac arrhythmias induced by activation of H1 and H2 
receptors are among the most serious consequences of mast cell degranulation. Several studies have 
shown the effectiveness of a premedication with a combination of H1R and H2R antagonists, for 
example dimetindene plus cimetidine [10,17–20]. 
The commercially available H1 and H2 antihistamines differ considerably concerning 
physicochemical and pharmacokinetic properties. A combination of both qualities of action in one 
hybrid drug could be of therapeutic advantage, for instance, in terms of pharmacokinetics. Such hybrid 
antihistamines could also be of potential interest in other indications, e.g., in the therapeutic 
management of atopic dermatitis. Icotidine (SK&F 93319), derived from the isocytosine series of H2R 
antagonists, was the first substance reported to possess nearly equipotent antagonist activity at both 
H1R and H2R [21] (Figure 1). 
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Figure 1. Icotidine (SK&F 93319) and lead compound 1. 
 
Previously, urea-type H1/H2 receptor antagonists such as compound 1 were synthesized and 
pharmacologically investigated [22–24]. Lessons learned, in particular from the H4R and H3R, suggest 
that differences between HxR species orthologues should to be taken into account [2,3]. Nevertheless, 
isolated guinea-pig organs have been used as standard pharmacological models to characterize H1R 
and H2R antagonists for many decades, and the data gained from these investigations provided a 
reliable basis for numerous successfully marketed histamine receptor antagonists. Therefore, with 
respect to potential studies in translational animal models, the synthesized compounds were 
investigated on the guinea pig isolated ileum and the spontaneously beating right atrium. The urea 
derivative 1, containing a three-membered carbon chain as a spacer and fluoropheniramine substructure, 
had a pKB value of 8.21 at the isolated guinea pig ileum and proved to be more active than pheniramine at 
the H1R. However, H2R antagonist activity (guinea pig atrium: pKB 6.68) was found to be moderate, 
presumably due to introduction of a basic centre close to the polar group [23] (Figure 1). 
As mepyramine (pA2 9.07 ± 0.03) [25] is more potent than pheniramine-like H1R antagonists, in the 
present study, the mepyramine partial structure was used as a building block for the synthesis of hybrid 
compounds. The H1R antagonist pharmacophoric moiety was connected via a carbon chain (spacer) of 
variable length and a cyanoguanidine group with the H2R antagonist partial structure of roxatidine, 
tiotidine, and ranitidine (Figure 2). Thereby, the cyanoguanidine moiety, a characteristic “urea 
equivalent” [26,27] of H2R antagonists such as cimetidine, was kept unchanged as a bioisosteric 
replacement of the polar moieties present in roxatidine, tiotidine and ranitidine, respectively. 
Figure 2. General structure of spacer-linked combined H1/H2 receptor antagonists. 
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2. Results and Discussion 
2.1. Chemistry 
The cyanoguanidines 14–35 were synthesized starting from triamines 4–13 which can be easily 
prepared from the secondary amines 3a and 3b through alkylation with acrylonitrile or  
ω-haloalkanenitriles of different chain lengths followed by reduction with LiAlH4 in diethyl ether 
(Scheme 1). Secondary amines 3a and 3b were obtained by acylation of primary amines 2a and 2b 
with ethyl chloroformate and subsequent reduction with LiAlH4 in tetrahydrofuran [23,24]. 
Scheme 1. Synthetic pathway for intermediates 4–13. 
 
Reagents and Conditions: a Ethylenediamine, pyridine, reflux, 3 h; b NaH, 4-methoxybenzylchloride (for 2a), 
4-fluorobenzylchloride (for 2b), DMSO, room temperature, 12 h; c NaOH, ethyl chloroformate, THF, room 
temperature; d (i) Acrylonitrile or corresponding ω-chloroalkylnitrile, KI, excess Na2CO3, 60 °C, 2 h;  
(ii) Lithium aluminum hydride (50% excess), diethyl ether, room temperature, 2 h. 
The triamines 4–13 were allowed to react with the isourea intermediates A1–D1 (Scheme 2) to 
yield the cyanoguanidines 14–35 [22–24,28–30]. Addition of the roxatidine-like primary amines A and 
B resulted in 14–23 and 24, respectively, while addition of C and D afforded the compounds 25–34 
and 35, respectively [24]. 
2.2. Pharmacology 
The synthesized hybrid compounds 14–35 were investigated for histamine H1R and H2R 
antagonism at the isolated guinea pig ileum (H1R) and the isolated spontaneously beating guinea pig 
right atrium (H2R). The results are summarized in Table 1. 
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Scheme 2. Synthetic pathway of cyanoguanidines 14–35. 
 
Reagents and Conditions: a Diphenyl N-cyanocarbonimidate, room temperature, 2 h; b Respective diamine, A1-D1, 
acetonitrile, reflux, 16 h. 
Compounds 14–35 showed histamine H1R antagonistic activities on guinea pig ileum with pKB 
values in the range from 6.8 (compound 14) to 8.6 (compounds 28, 32). Although the activity 
increased with the length of the polymethylene spacer in case of the methoxy-substituted derivatives 
bearing a roxatidine-like H2-antagonist moiety (compound 14 vs. 16, 18 and 21), a clear general 
tendency was not obvious, neither for the corresponding fluorinated analogues nor for the 
guanidinothiazoles 25–34. Highest H1R antagonistic activity resided in the latter group of compounds. 
Though an affinity-increasing effect was not evident, it should be noted that the interactions with the 
H1R were not dramatically affected in an adverse manner by the H2R antagonist moiety. The most 
potent H1R antagonists achieved KB values in the one-digit nanomolar range corresponding to about 30% 
of the activity of mepyramine at the guinea-pig ileum. 
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Table 1. Histamine H1 and H2 receptor antagonism of cyanoguanidines 14–35. 
 
     H1 Receptor Antagonism  H2 Receptor Antagonism 
Compound R1 y R2  pKB a 
rel. 
activity 
conc. [M] 
 
pKB a 
rel.  
activity 
conc. [M] 
Mepyramine - - -  9.07 b 100   -   
Cimetidine - - -  -    6.40 100  
Icotidine c - - -  7.77 5.0   7.49 1230  
1 d     8.21 14 0.3 × 10−6  6.68 190 10−6–0.3 × 10−5 
14 OCH3 2 A  6.88 1 0.3 × 10−6  6.63 170 10−7–0.3 × 10−6 
15 F 2 A  7.83 6 10−7  5.97 e 37 0.3 × 10−5 
16 OCH3 3 A  7.81 6 10−7–0.3 × 10−6  6.37 93 0.3 × 10−6 
17 F 3 A  7.77 e 5 10−7–0.3 × 10−6  6.0 40 0.3 × 10−6–10−6 
18 OCH3 4 A  7.76 5 10−8–10−7  6.38 96 0.3 × 10−6 
19 F 4 A  7.75 5 10−7–0.3 × 10−7  5.76 e 23 10−5–0.3 × 10−5 
20 F 5 A  7.95 7 10−7  5.67 19 0.3 × 10−5 
21 OCH3 6 A  8.42 22 10−7–0.3 × 10−7  6.43 107 0.3 × 10−6 
22 F 6 A  8.06 10 10−7–0.3 × 10−7  6.41 102 10−6 
23 F 7 A  7.93 7 10−7–0.3 × 10−7  6.17 59 10−6–0.3 × 10−5 
24 F 4 B  7.65 4 10−7–0.3 × 10−6  6.07 47 10−6 
25 OCH3 2 C  8.05 10 10−7–0.3 × 10−7  7.37 933 10−7 
26 F 2 C  7.94 7 10−8–0.3 × 10−7  6.62 166 10−6 
27 OCH3 3 C  8.21 14 10−8–0.3 × 10−7  6.52 132 10−6 
28 F 3 C  8.62 36 10−8–0.3 × 10−8  6.47 118 0.3 × 10−6–0.3 × 10−5 
29 OCH3 4 C  7.91 7 0.3 × 10−7  7.00 398 10−7–0.3 × 10−6 
30 F 4 C  8.32 18 10−8–0.3 × 10−8  6.28 76 10−6 
31 F 5 C  8.36 20 10−8–0.3 × 10−7  6.51 129 10−6–10−5 
32 OCH3 6 C  8.61 35 10−7–0.3 × 10−7  6.61 162 10−7–0.3 × 10−6 
33 F 6 C  8.44 23 0.3 × 10−7  6.52 132 10−6 
34 F 7 C  8.15 12 10−8  7.02 417 10−6–0.3 × 10−6 
35 OCH3 3 D  7.95 7 10−8–10−7  5.22 e 7 10−5 
a Determined at the isolated ileum (H1) and right atrium (H2) of the guinea pig; pKB mean values, S.E.M. for 
ileum within ±0.2 by 16, 17, 18, and 19; ±0.1 by all other compounds; pKB mean values, S.E.M. for atrium 
within ±0.2 by 14, and 17; ±0.1 by all other compounds; rel. activity, % activity relative to mepyramine, 
icotidine or cimetidine, respectively; antag. conc., antagonist concentrations used; b [25]; c [21]; d [23];  
e At 0.3 × 10−6 M, depression of the concentration response curve by 15%, 30%, 15%, and 20% for 15, 17,  
and 19, respectively. 
It is well known from numerous investigational and commercially available H2R antagonists  
(e.g., cimetidine, ranitidine or tiotidine) that, comparing the numeric values, the highest antagonistic 
activities achievable at the guinea pig right atrium (Table 1) are usually by one to two orders of 
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magnitude lower than at the guinea pig ileum. The same holds for the investigated hybrid compounds. 
Highest H2R antagonistic activity resided in guanidinothiazole 25 with a pKB value of 7.37, 
corresponding to nine-fold higher activity than cimetidine or three-fold lower activity than tiotidine, 
respectively. Among the cyanoguanidines substituted with roxatidine-like partial structures 
(compounds 14–23), lengthening of the spacer from ethylene to pentamethylene decreased both 
antagonist activities on H1 and H2 receptors. However, cyanoguanidine derivative 21 (pKB ileum, 8.42, 
pKB atrium, 6.43) with a hexamethylene spacer separating the basic center from the polar 
cyanoguanidine moiety was approximately two times more active on H1 receptors, and the H2 
antagonistic activity was in the same range as that of reference compounds 1 or cimetidine. Moreover, 
the presence of a methoxy group at p-position of the mepyramine partial structure seemed to be of 
advantage over fluorine substitution. Compared to 22, the H1R antagonist activity of 21 was 
approximately twofold higher whereas the H2R antagonist remained unchanged. Further extension of 
the spacer up to seven methylene groups in the H1R antagonist partial structure or up to four methylene 
groups in the H2R antagonist moiety decreased both H1R and H2R antagonistic activities as 
demonstrated by cyanoguanidine derivatives 23 (pKB ileum, 7.93, pKB atrium, 6.17) and 24  
(pKB ileum, 7.65, pKB atrium, 6.07), respectively. Thus, compound 21 represents the optimum in terms 
of combined H1R/H2R antagonistic activity among the piperidinomethylphenoxyalkylcyanoguanidines. 
A further increase in potency was achieved by replacement of the roxatidine-like moiety with a 
guanidinothiazole (compounds 25–34) as in tiotidine, resulting in the highest histamine H1R and H2R 
antagonistic activities among this series of pharmacological hybrids. Compound 32 with a 
hexamethylene spacer was found to be up to two times more potent at both H1R and H2R compared to 
the roxatidine-like analog 21. In addition, the results revealed that a p-methoxy moiety (compound 32), 
unlike p-fluoro substituent (compound 33), potentiates the antagonistic activities at both H1 and H2 
receptors. Remarkably, further extension of the spacer up to 7 methylene groups resulted in 
cyanoguanidine derivative 34, the most potent H2R antagonist amid the title compounds. However, 
H1R antagonistic decreased up to 5-fold compared to compounds 32 and 33. The cyanoguanidine 
derivative 35, bearing a ranitidine-like moiety, did not show an activity-enhancing effect compared to 
the corresponding parent compounds. Compound 25 with an ethylene spacer and tiotidine partial 
structure revealed the highest H2R antagonistic activity among the presented series of compounds. 
In summary, the combination of the mepyramine substructure with a tiotidine-like guanidinothiazole 
turned out to be most suitable to obtain pharmacological hybrid with activities comparable to those of 
commercially available selective H1R and H2R antagonists. 
3. Experimental 
3.1. Chemistry 
3.1.1. General Conditions  
Melting points are uncorrected and determined in open capillaries in a Buechi 512 Dr. Tottoli 
apparatus. 1H-NMR spectra were recorded on a Bruker WC 300 spectrometer with tetramethylsilane 
(TMS) as internal standard. Chemical shifts are reported in ppm downfield from internal 
tetramethylsilane as reference. 1H-NMR signals are reported in order: multiplicity (s, single;  
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d, doublet; t, triplet; q, quintet; m, multiplet; br, broad; *, exchangeable by D2O), number of protons, 
and approximate coupling constants in Hertz. Elemental analyses were performed on Perkin-Elmer 
240B and 240C instruments. Analyses (C, H, N) indicated by the symbols of elements were within 
±0.4% of the theoretical values. Chromatographic separations were done by rotation planar 
chromatography (centrifugal layer chromatography) using a Chromatotron Model 7924 (Harrison 
Research, Muttenz, Switzerland) with 4-mm layers of silica gel 60 PF254 containing gypsum (Merck). 
To avoid tailing, a saturated ammonia atmosphere was produced by passing through a stream of 
anhydrous gaseous ammonia via the “inert gas inlet” of the Chromatotron. EI-mass spectra were 
recorded using Finnigan MAT CH7A (70 eV), Finnigan MAT 711 (80 eV), or Kratos MS 25 RF (70 eV). 
+FAB-MS spectra were recorded on Finnigan MAT CH5DF instrument (xenon, DMSO)/glycerol). The 
following abbreviations are used: DMF, N,N-dimethylformamide,; EtOH, ethanol; Et2O, diethyl ether; 
MeOH, methanol; Me2SO, dimethyl sulfoxide; Ph, phenyl; * exchangeable with D2O; C2H2O4, oxalic 
acid; Py, pyridyl; Pip, piperidyl; TA, C4H6O6, tartaric acid; C20H18O8, (−)-di-p-tolyltartaric acid; 
decomp, decomposition. 
3.1.2. Synthesis of Primary Amines 2a and 2b 
2-Bromopyridine (109.30 mmol) and ethylenediamine (546 mmol) were refluxed in pyridine for 3 h. 
Excess of ethylenediamine was evaporated under reduced pressure, water was added, the pH value was 
adjusted to >11 using NaOH (1N), and the 2-(2-aminoethylamino)-pyridine was extracted with 
chloroform [29]. After evaporation of chloroform, the product was purified by means of a 
Chromatotron (chloroform/methanol, 97/3, V/V, ammonia atmosphere), and used in the following 
reaction without further purifications. The primary amines 2a and 2b were synthesized by suspending  
2-(2-aminoethylamino)pyridine (73.40 mmol) with sodium hydride (60% oil suspension, 64.50 mmol) 
in DMSO under nitrogen atmosphere. The reaction temperature was increased gradually and kept at 85 °C 
until hydrogen evolution ceased. For synthesis of 2a and 2b, 4-methoxybenzylchloride and  
4-fluorobenzylchloride, respectively, were added, and the mixture was stirred for 12 h at room 
temperature. Subsequently, water (500 mL) was added, 2a and 2b were extracted with diethyl ether at 
pH > 11, combined extracts were dried over anhydrous potassium carbonate, and the solvent was 
evaporated under reduced pressure yielding the oily products 2a and 2b, which were used in the 
following reaction to prepare 3a and 3b without further purification. 
3.1.3. Synthesis of Secondary Amines 3a and 3b 
For synthesis of 3a and 3b, 43.64 mmol of the corresponding primary amine 2a and 2b were 
dissolved in diethyl ether, NaOH (10%) was added and the solution was kept over ice-bath. Ethyl 
chloroformate was added gradually to the two-phase system. After complete reaction, the diethyl ether 
layer was separated, dried over sodium sulfate, and evaporated under reduced pressure to yield the oily 
products 3a and 3b, respectively [22–24,28]. 
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3.1.4. General Procedure for the Synthesis of the Diamines 4–13 
As previously described, a mixture of the corresponding secondary amine 3a or 3b (10–30 mmol), 
an equimolar amount of the pertinent ω-halonitrile, a catalytic amount of potassium iodide and a 100% 
excess of sodium carbonate was stirred for 2 h at 60 °C in 20 mL of a mixture of acetonitrile and 
dimethylformamide (1:1 (V/V) in case of chloroacetonitrile, 9:1 (V/V) in case of homologous 
halonitriles) [22–24,28]. Subsequently, water was added, the mixture was extracted with toluene, the 
combined extracts were dried over sodium sulfate and evaporated under reduced pressure yielding the 
corresponding oily aminonitriles as intermediates, which were dissolved in 20 mL of anhydrous 
diethyl ether and dropped to an ice-cold suspension of lithium aluminium hydride (50% excess). After 
2 h stirring at room temperature the reaction mixture was hydrolyzed by addition of water followed by 
3 mL of a 10% aqueous sodium hydroxide solution. The resulting diamines 4–13 were purified 
chromatographically (Chromatotron, eluent: chloroform/methanol, gradient from 99:1 to 90:10 (V/V), 
ammonia atmosphere), and were used in the following reactions for synthesis of cyanoguanidines  
14–35 [22–24,28]. 
3.1.5. General Procedure for the Synthesis of Cyanoguanidines 14–35 
The pertinent N-cyano O-phenyl isoureas (2–4 mmol) A1–D1, which were prepared by stirring of 
equivalent amounts of A–D with diphenyl N-cyanocarbonimidate for 2 h, and equimolar amounts of 
the respective diamines 4–13 in 30 mL of anhydrous acetonitrile, were heated under reflux for 16 h. 
The mixture was evaporated to dryness and the cyanoguanidines 14–35 were isolated 
chromatographically (Chromatotron, chloroform: methanol, gradient from 99:1 to 90:10, ammonia 
atmosphere) [22–24,28]. 
N-Cyano-N'-[2-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]ethyl]-N″-[3-
[3-(piperidinomethyl)phenoxy]propyl]guanidine (14). Yield: 65%, mp: 88–89 °C; 1H-NMR (CDCl3): 
δ ppm = 1.41–1.42 (m, 2H, PipH); 1.53–1.57 (m, 4H, PipH), 1.98 (m, 2H, CH2); 2.25 (s, 3H, N-CH3); 
2.34 (br, 4H, PipH); 2.57–2.62 (m, 4H, 2(CH2-NCH3)); 3.20–3.21 (m, 2H, CH2-NH); 3.30–3.32  
(m, 2H, CH2-NH); 3.40 (s, 2H, Ph-CH2- Pip); 3.66 (t, J = 7, 2H, CH2-N); 3.76 (s, 3H, Ph-OCH3); 3.97 
(t, J = 6, 2H, Ph-O-CH2); 4.60 (s, 2H, Ph-CH2-N); 5.85 (br, 1H*, NH); 6.40-6.43 (d, J = 9, 1H 
aromatic, Py5-H); 6.51–6.55 (m, 1H aromatic, Py3-H); 6.73–6.75 (d, J = 8.5, 1H aromatic, 4-H);  
6.81–6.84 (d, J = 8, 2H aromatic, 2-H); 6.87-6.90 (d, J = 8, 2H aromatic, 2-H); 7.10–7.13 (m, 2H 
aromatic, 3-H); 7.10–7.13 (br, 1H*, NH); 7.17 (t, J = 8, 1H aromatic, 3-H); 7.36 (m, 1H aromatic,Py4-H); 
8.12–8.13 (d, J = 3, 1H aromatic, Py6-H); MS: m/z (%) 612 (M+, 1), 121 (100); Anal. Calcd. for 
C35H48N8O2·H2O: C, 66.60; H, 7.99; N, 17.80. Found: C, 66.70; H, 7.82; N, 17.45. 
N-Cyano-N'-[2-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]ethyl]-N″-[3-[3-
(piperidinomethyl)phenoxy]propyl]guanidine (15). Yield: 33%, mp: 106–108 °C; 1H-NMR (CDCl3):  
δ ppm = 1.44 (m, 2H, PipH); 1.61 (m, 4H, PipH), 1.90 (m, 2H, CH2); 2.31 (s, 3H, N-CH3); 2.59–2.64 
(br, 4H, PipH); 2.71 (m, 4H, 2(CH2-NCH3)); 3.24 (m, 2H, CH2-NH); 3.37–3.47 (m, 2H, CH2-NH); 
3.63 (m, 2H, CH2-N); 3.83 (s, 2H, Ph-CH2-Pip); 3.96 (t, 2H, Ph-O-CH2); 4.18 (s, 6H, TA); 4.72 (s, 2H, 
Ph-CH2-N); 5.20–5.60 (br, 6H*, TA-OH); 6.54 (m, 2H aromatic, Py5-H, Py3-H); 6.86–6.88 (m, 3H 
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aromatic, 4-H, 2-H); 6.86–6.88 (br, 3H*, 3(H-(N+)); 6.92 (m, 2H aromatic, 2-H); 6.92 (br, 1H*, NH); 
7.11 (m, 2H aromatic, 3-H); 7.25 (m, 2H aromatic, 3-H); 7.25 (br, 1H*, NH); 7.45 (m, 1H aromatic, 
Py4-H); 8.06 (d, 1H aromatic, Py6-H); 10.50 (br, 3H*, TA-COOH); MS: m/z (%) 601 (M+, 7), 76 
(100); Anal. Calcd. for C34H45FN8O·3C4H6O6: C, 52.60; H, 6.04; N, 10.70. Found: C, 52.50; H, 6.27; 
N, 10.60. 
N-Cyano-N'-[3-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]propyl]-N″-
[3[3-piperidinomethyl)phenoxy]propyl]guanidine (16). Yield: 51%, mp: 62–65 °C; 1H-NMR (CDCl3): 
δ ppm = 1.41–1.42 (m, 2H, PipH); 1.53–1.57 (m, 4H, PipH), 1.66 (m, 2H, CH2); 2.25 (s, 3H, N-CH3); 
2.34 (br, 4H, PipH); 2.57–2.62 (m, 4H, 2(CH2-NCH3)); 3.20–3.21 (m, 2H, CH2-NH); 3.30–3.32 (m, 
2H, CH2-NH); 3.40 (s, 2H, Ph-CH2- Pip); 3.66 (t, J = 7, 2H, CH2-N); 3.76 (s, 3H, Ph-OCH3); 3.97  
(t, J = 6, 2H, Ph-O-CH2); 4.60 (s, 2H, Ph-CH2-N); 5.85 (br, 1H*, NH); 6.40–6.43 (d, J = 9, 1H 
aromatic, Py5-H); 6.51–6.55 (m, 1H aromatic, Py3-H); 6.73–6.75 (d, J=8.5, 1H aromatic, 4-H);  
6.81–6.84 (d, J = 8, 2H aromatic, 2-H); 6.87–6.90 (d, J = 8, 2H aromatic, 2-H); 7.10–7.13 (m, 2H 
aromatic, 3-H); 7.10–7.13 (br, 1H*, NH); 7.17 (t, J = 8, 1H aromatic, 3-H); 7.36 (m, 1H aromatic, Py4-H); 
8.12–8.13 (d, J = 3, 1H aromatic, Py6-H); MS: m/z (%) 627 (M+, 6), 241 (11), 121 (100); Anal. Calcd. 
for C36H50N8O2: C, 69.0; H, 8.04; N, 17.90. Found: C, 68.80; H, 8.27; N, 17.70. 
N-Cyano-N'-[3-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]propyl]-N″-[3-
[3-(piperidinomethyl)phenoxy]propyl]guanidine (17). Yield: 57%, mp: 65–68 °C; 1H-NMR (CDCl3):  
δ ppm = 1.43 (m, 2H, PipH); 1.57–1.61 (m, 4H, PipH); 1.68 (m, 2H, CH2); 1.99–2.05 (m, 2H, CH2); 
2.28 (s, 3H, N-CH3); 2.40 (br, 4H, PipH); 2.51 (t, J = 7, 2H, CH2-NCH3); 2.58 (t, J = 7, 2H, CH2-N-
CH3); 3.25–3.26 (m, 2H, CH2-NH); 3.39 (m, 2H, CH2-NH); 3.45 (s, 2H, Ph-CH2-Pip); 3.70 (t, J = 7.5, 
2H, CH2-N); 4.03 (t, J = 6, 2H, Ph-O-CH2); 4.63 (s, 2H, Ph-CH2-N); 6.41 (d, J = 9, 1H aromatic, Py5-
H); 6.55 (t, J = 6, 1H aromatic, Py3-H); 6.75–6.78 (d, J = 8, 1H aromatic, 4-H); 6.89-6.92 (d, J = 6, 2H 
aromatic, 2-H); 6.89–6.92 (br, 1H*, NH); 6.97 (t, J = 8, 2H aromatic, 2-H), 7.13–7.21 (m, 2H 
aromatic, 3-H, 3-H); 7.13–7.21 (br, 1H*, NH); 7.38 (t, J = 7, 1H aromatic, Py4-H); 8.12–8.13 (d, J = 5, 
1H aromatic, Py6-H); MS: m/z (%) 615 (M+, 14), 229 (100), 109 (96); Anal. Calcd. for 
C35H47FN8O·3C4H6O6: C, 68.80; H, 8.27; N, 17.70. Found: C, 68.53; H, 8.55; N, 17.21. 
N-Cyano-N'-[4-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]butyl]-N″-[3-
[3-(piperidinomethyl)phenoxy]propyl]guanidine (18). Yield: 47%, mp: 106–108 °C; 1H-NMR 
(CDCl3): δ ppm = 1.44 (m, 4H, PipH); 1.59 (m, 6H, PipH); 1.91 (m, 2H, CH2); 2.50 (s, 3H, N-CH3); 
2.64 (m, 4H, PipH); 2.86 (m, 2H, CH2-N-CH3); 3.11 (m, 2H, CH2-NCH3); 3.28 (m, 4H, CH2-NH,  
Ph-CH2-Pip); 3.44 (m, 2H, CH2-NH); 3.71 (s, 3H, Ph-OCH3); 3.75 (m, 2H, CH2-N), 3.97 (m, 2H, Ph-
O-CH2); 4.12 (s, 6H, TA); 4.65 (s, 2H, Ph-CH2-N); 6.00 (br, 6H*), TA-OH); 6.55–6.58 (m, 2H 
aromatic, Py5-H, Py3-H); 6.86–6.88 (m, 3H aromatic, 4-H, 2-H); 6.86–6.88 (br, 4H*), 3 (H-(N+)), 
NH); 6.92–7.00 (m, 2H aromatic, 2-H); 7.06 (br, 1H*, NH); 7.13 (m, 2H aromatic, 3-H); 7.26 (m, 1H 
aromatic, 3-H); 7.43–7.46 (d, J = 7, 1H aromatic, Py4-H); 8.08 (m, 1H aromatic, Py6-H); 10.50 (br, 
3H*), TA-COOH); MS: m/z (%) 641 (M+, 1), 241 (7), 121 (100); Anal. Calcd. for 
C37H52N8O2·3C4H6O6: C, 51.60; H, 6.29; N, 10.20. Found: C, 52.01; H, 6.47; N, 10.30. 
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N-Cyano-N'-[4-[N-[2-[N-(4-fluorobenzyl]-N-(2-pyridyl)amino]ethyl]-N-methylamino]butyl]-N″-[3-[3-
(piperidinomethyl)phenoxy]propyl]guanidine (19). Yield: 48%, mp: 84–86 °C; 1H-NMR (CDCl3):  
δ ppm = 1.37 (m, 2H, CH2); 1.46 (m, 2H, CH2); (see 15); MS: m/z (%) 629 (M+, 5), 2229 (84), 109 (100); 
Anal. Calcd. for C36H49FN8O·3C4H6O6: C, 53.90; H, 6.73; N, 10.40. Found: C, 51.30; H, 6.46; N, 9.97. 
N-Cyano-N'-[4-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]pentyl]-N″-
[3-[3-(piperidinomethyl)phenoxy]propyl]guanidine (20). Yield: 17%, mp: 86–88 °C; 1H-NMR 
(CDCl3): δ ppm = 1.22 (m, 4H, 2(CH2)); (see 17); MS: m/z (%) 643 (M+, 7), 229 (54), 154 (100); Anal. 
Calcd. for C37H51FN8O·3C4H6O6: C, 53.80; H, 6.36; N, 10.30. Found: C, 54.30; H, 6.83; N, 10.30. 
N-Cyano-N'-[6-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]hexyl]-N″-[3-
[3-(piperidinomethyl)phenoxy]propyl]guanidine (21) Yield: 66%, mp: 79–81 °C; 1H-NMR (CDCl3):  
δ ppm = 1.23–1.25 (m, 4H, 2(CH2)); 1.42–1.43 (m, 4H, 2(CH2)); (see 14); MS: m/z (%) 669 (M+, 5), 
121 (100); Anal. Calcd. for C39H56N8O2·3C4H6O6: C, 54.70; H, 6.66; N, 10.10. Found: C, 54.60; H, 
7.01; N, 9.79. 
N-Cyano-N'-[6-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]hexyl]-N″-[3-
[3-(piperidinomethyl)phenoxy]propyl]guanidine (22). Yield: 35%, mp: >58 °C decomposed; 1H-NMR 
(CDCl3): δ ppm = 1.25 (m, 4H, 2(CH2)); 1.42 (m, 2H, CH2); (see 25); MS: m/z (%) 657 (M+, 11), 229 
(100); Anal. Calcd. for C38H53FN8O·3C4H6O6: C, 52.50; H, 6.61; N, 9.80. Found: C, 52.70; H, 6.80;  
N, 9.80. 
N-Cyano-N'-[7-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]heptyl]-N″-[3-
[3-(4-(piperidin-1-ylmethyl)phenoxy]propyl]guanidine (23). Yield: 41%, mp: 96–98 °C; 1H-NMR 
(CDCl3): δ ppm = 1.21-1.25 (m, 6H, 3(CH2)); 1.42 (m, 2H, CH2); (see 17); MS: m/z (%) 671 (M+, 3), 
229 (100); Anal. Calcd. for C39H55FN8O·1.5C20H18O8: C, 65.30; H, 6.62; N, 8.83. Found: C, 65.24;  
H, 6.90; N, 8.65. 
N-Cyano-N'-[4-[N-[2-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]butyl)-N″-[3-[4-(4-
(piperidin-1-ylmethyl)phenoxy]butyl]guanidine (24). Yield: 37%, mp: 102–104 °C; 1H-NMR (CDCl3): 
δ ppm = 1.68-1.75(m, 2H, CH2); (see 17); MS: m/z (%) 629 (M+, 18), 229 (98), 109 (100); Anal. 
Calcd. for C36H49FN8O·1.5C20H18O8: C, 64.60; H, 6.36; N, 9.13. Found: C, 64.40; H, 6.51; N, 8.77. 
N-Cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[2-[N-[2-[N-(4-methoxybenzyl)-N-
(2-pyridyl)amino]ethyl]-N-methylamino]ethyl]guanidine (25). Yield: 58%, mp: 56–58 °C; 1H-NMR 
(CDCl3): δ ppm = 2.23 (s, 3H, N-CH3); 2.50 (m, 4H, CH2-S, CH2-NCH3); 2.56 (m, 2H, CH2-NCH3); 
3.16–3.17 (m, 2H, CH2-NH); 3.26–3.28 (m, 2H, CH2-NH); 3.37 (s, 2H, Thi-CH2-S); 3.58 (m, 2H, 
CH2-N); 3.70 (s, 3H, Ph-OCH3); 4.66 (s, 2H, Ph-CH2-N); 6.45 (s, 1H aromatic., Thi5-H); 6.50–6.54 
(m, 2H aromatic, Py5-H, Py3-H);, 6.84–6.87 (m, 2H aromatic, 2-H); 6.84–6.87 (br, 2H*, 2(NH)); 6.94 
(br, 4H*, NC(NH2)2); 7.14 (d, J = 8, 2H aromatic, 3-H); 7.41 (m, 1H aromatic, Py4-H); 8.05–8.07  
(d, J = 4, 1H aromatic, Py6-H); MS: m/z (%) 596 (M+, 2), 121 (100); Anal. Calcd. for 
C27H37N11OS2·1.5C2H2O4: C, 54.30; H, 6.75; N, 24.0. Found: C, 54.21; H, 6.63; N, 24.11. 
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N-Cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[2-[N-[2-[N-(4-fluoro-benzyl)-N-(2-
pyridyl)amino]ethyl]-N-methylamino]ethyl]guanidine (26). Yield: 50%, mp: >109 °C decomposed;  
1H-NMR (CDCl3): δ ppm = 2.23 (s, 3H, N-CH3); 2.50 (m, 2H, CH2-S); 2.55 (m, 4H, 2(CH2-NCH3)); 
3.15 (m, 2H, CH2-NH); 3.27 (m, 2H, CH2-NH); 3.58 (m, 4H, Thi-CH2-S, CH2-N); 4.72 (s, 2H, Ph-
CH2-N); 6.46 (s, 1H, Thi5-H); 6.51–6.54 (m, 2H aromatic, Py5-H, Py3-H); 6.80 (br, 6H*, 2(NH), 
NC(NH2)2); 7.11 (t, J=9, 2H aromatic, 2-H); 7.22–7.24 (d, J=6, 2H aromatic, 3-H); 7.44 (m, 1H 
aromatic, Py4-H); 8.06 (d, 1H aromatic, Py6-H); MS: m/z (%) 584 (M+, 3), 121 (100); Anal. Calcd. for 
C26H34FN11S2·2C4H6O6·1.5H2O: C, 44.80; H, 5.42; N, 16.90. Found: C, 44.61; H, 4.91; N, 17.11. 
N-Cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[3-[N-[2-[N-(4-methoxybenzyl)-N-
(2-pyridyl)amino]ethyl]-N-methylamino]propyl]guanidine (27). Yield: 45%, mp: 54–56 °C; 1H-NMR 
(CDCl3): δ ppm = 1.66 (m, 2H, CH2); 2.26 (s, 3H, N-CH3); 2.48 (m, 2H, CH2-S); 2.58 (t, J = 7, 2H, 
CH2-NCH3); 2.68 (t, J = 7, 2H, CH2-NCH3); 3.21 (m, 2H, CH2-NH); 3.29 (m, 2H, CH2-NH); 3.58  
(s, 2H, Thi-CH2-S); 3.72 (t, J = 8, 2H, CH2-N); 3.76 (s, 3H, Ph-OCH3); 4.60 (s, 2H, Ph-CH2-N); 5.74 
(br, 2H*, 2(NH)); 6.33 (S, 1H aromatic, Thi5-H); 6.43–6.44 (d, J = 8.5, 2H aromatic, Py5-H, Py3-H); 
6.54 (br, 4H*, NC(NH2)2); 6.81–6.84 (m, 2H aromatic, 2-H); 7.10–7.13 (d, J=8,5, 2H aromatic, 3-H); 
7.34–7.39 (m, 1H aromatic, Py4-H); 8.11–8.12 (d, J=3, 1H aromatic, Py6-H); MS: m/z (%) 624 (M+, 
1), 121 (100); Anal. Calcd. for C28H39N11OS2·H2O: C, 53.60; H, 6.58; N, 24.50. Found: C, 53.81; H, 
6.43; N, 24.41. 
N-Cyano-N'-[3-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]propyl]-N″-[2-
[[2-guanidino-4-thiazolyl)methyl]thio]ethyl]guanidine (28). Yield: 35%, mp: oil; 1H-NMR (CDCl3):  
δ ppm = 1.67 (m, 2H ,CH2); 2.27 (s, 3H, N-CH3); 2.49 (t, 2H, CH2-S); 2.58 (t, 2H, CH2, NCH3); 2.73 
(t, 2H, CH2-NCH3); 3.21 (m, 2H, CH2-NH); 3.32 (m, 2H, CH2-NH); 3.60 (s, 2H, Thi-CH2-S); 3.73 (m, 
2H, CH2-N); 4.66 (s, 2H, Ph-CH2-N); 6.35 (s, 1H aromatic, Thi5-H); 6.41–6.43 (d, J = 9, 1H aromatic, 
Py5-H); 6.57 (t, J = 5, 1H aromatic, Py3-H); 6.80 (br, 6H*, 2(NH), NC(NH2)2); 6.99 (t, J=8.5, 2H 
aromatic, 2-H); 7.17 (m, 2H aromatic, 3H); 7.37–7.39 (m, 1H aromatic, Py4-H); 8.14 (d, 1H, Py6-H); 
MS: m/z (%) 598 (M+, 2), 121 (100); Anal. Calcd. for C27H36FN11S2: C, 53.80; H, 6.58; N, 24.50. 
Found: C, 53.81; H, 6.43; N, 24.40. 
N-Cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[4-[N-[2-[N-(4-methoxybenzyl)-N-
(2-pyridyl)amino]ethyl]-N-methylamino]butyl]guanidine (29). Yield: 60%, mp: hygroscopic foam;  
1H-NMR (CDCl3): δ ppm = 1.36–1.44 (m, 4H, 2(CH2)); (see 25); MS: m/z (%) 624 (M+, 1), 121 (100); 
Anal. Calcd. for C29H41N11OS2·1.5H2O: C, 53.50; H, 6.81; N, 23.70. Found: C, 53.42; H, 6.51; N, 24.01. 
N-Cyano-N'-[4-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]butyl]-N″-[2-
[[2-guanidino-4-thiazolyl)methyl]thio]ethyl]guanidine (30). Yield: 60%, mp: >137 °C decomposed; 
1H-NMR (CDCl3): δ ppm = 1.49–1.58 (m, 2H, CH2); (see 28); MS: m/z (%) 612 (M+, 2), 229 (100), 
109 (38); Anal. Calcd. for C28H38FN11S2·1.5C20H18O8·2H2O: C, 56.80; H, 5.66; N, 12.60. Found: C, 
56.40; H, 5.30; N, 12.51. 
N-Cyano-N'-[5-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]pentyl]-N″-[2-
[[2-guanidino-4-thiazolyl)methyl]thio]ethyl]guanidine (31). Yield: 29%, mp: 103–105 °C; 1H-NMR 
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(CDCl3): δ ppm = 1.23 (m, 2H, CH2); 1.35 (m, 4H, 2(CH2)); (see 26); MS: m/z (%) 626 (M+, 3), 154 
(100); Anal. Calcd. for C29H40FN11S2·3C4H6O6·0.5H2O: C, 45.40; H, 5.48; N, 14.20. Found: C, 45.12; 
H, 5.32; N, 14.19. 
N-Cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N″-[6-[N-[2-[N-(4-methoxybenzyl)-N-
(2-pyridyl)amino]ethyl]-N-methylamino]hexyl]guanidine (32). Yield: 29%, mp: >52 °C decomp.;  
1H-NMR (CDCl3): δ ppm = 1.27 (m, 4H, 2(CH2)); 1.42 (m, 2H, CH2); (see 27); MS: m/z (%) 652  
(M+, 12), 121 (100); Anal. Calcd. for C31H45N11OS2·0.5H2O: C, 56.31; H, 7.01; N, 23.30. Found: C, 
56.42; H, 7.17; N, 23.31. 
N-Cyano-N'-[6-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]hexyl]-N″-[2-
[[2-guanidino-4-thiazolyl)methyl]thio]ethyl]guanidine (33). Yield: 61%, mp: 75–77 °C decomp.;  
1H-NMR (CDCl3): δ ppm = 1.26 (m, 4H, 2(CH2)); 1.43 (m, 2H, CH2); (see 28); MS: m/z (%) 639 (M+, 
9), 229 (100), 109 (88); Anal. Calcd. for C30H42FN11S2·3C4H6O6·0.25H2O: C, 46.10; H, 5.57; N, 
14.10. Found: C, 45.81; H, 5.62; N, 14.62. 
N-Cyano-N'-[7-[N-[2-[N-(4-fluorobenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]heptyl]-N″-[2-
[[2-guanidino-4-thiazolyl)methyl]thio]ethyl]guanidine (34). Yield: 24%, mp: 118–120 °C; 1H-NMR 
(CDCl3): δ ppm = 1.24 (m, 6H, 3(CH2)); 1.42 (m, 2H, CH2); (see 28); MS: m/z (%) 654 (M+, 2), 91 
(100); Anal. Calcd. for C31H44FN11S2·1.5C20H18O8·2H2O: C, 57.71; H, 5.96; N, 12.11. Found: C, 
57.61; H, 5.51; N, 12.42. 
N-Cyano-N'-[3-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]propyl]-N″-
[2-[5-(dimethylaminomethyl)furfuryl]thio]-ethyl]guanidine (35). Yield: 38%, mp: 74–76 °C; 1H-NMR 
(CDCl3): δ ppm = 1.68 (q, 2H, CH2); 2.23 (s, 6H, N(CH3)2); 2.28 (s, 3H, N-CH3); 2.49 (t, 2H, CH2-S); 
2.56–2.65 (m, 4H, 2(CH2-NCH3)); 3.23–3.30 (m, 4H, 2(CH2-NH)); 3.40 (s, 2H, Fur-CH2-S); 3.67 (s, 
2H, Fur-CH2-N); 3.75 (t, J = 8, 2H, CH2-N); 3.78 (s, 3H, Ph-OCH3); 4.63 (s, 2H, Ph-CH2-N);  
6.11–6.12 (q, J = 4, 2H aromatic, Fur3-H, Fur4-H); 6.44–6.47 (d, J = 8.5, 1H aromatic, Py5-H); 6.55 
(m, 1H aromatic, Py3-H); 6.55 (br, 1H*, NH); 6.83–6.85 (d, J = 8.5, 2H aromatic, 2-H); 6.83–6.85 (br, 
1H*); 7.12–7.15 (d, J = 8.5, 2H aromatic, 3-H); 7.38 (m, 1H aromatic, Py4-H); 8.12–8.13 (d,  
J = 3, 1H aromatic, Py6-H); MS: m/z (%) 595 (M+, 4), 121 (100); Anal. Calcd. for 
C31H44N8O2S·3C4H6O6·0.5H2O: C, 49.10; H, 6.03; N, 10.71. Found: C, 48.71; H, 6.26; N, 11.22. 
3.2. Pharmacology 
3.2.1. Histamine H1 Receptor Antagonist Activity on the Isolated Guinea Pig Ileum 
H1 receptor antagonist activity was determined from isotonically recorded (load 10 mN) cumulative 
concentration-response curves as described using histamine dihydrochloride (0.01–3 µM) as the 
reference agonist [31]. Whole segments of proximal ileum were mounted in an organ bath containing 
20 mL of Tyrode solution ([mM] NaCl 137, KCl 2.7, NaH2PO4 4.2, NaHCO3 11.9, CaCl2 1.8, MgCl2 
1.0, D-glucose 5.6) containing 0.1 µM atropine, aerated with 95% O2/5% CO2, bath temperature 37 °C. 
The compounds were tested at different concentrations with at least four experiments for each 
concentration. Determination of H1 receptor antagonism at low concentrations (≤10−8 M) of the 
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potential antagonists required a longer incubation period up to 20 min in order to achieve equilibrium 
states; at higher concentrations periods of 10–15 min were sufficient. pKB values (mean of at least 
three independent experiments) were calculated from the expression pKB = −log [antagonist] + log 
(concentration ratio–1) as the compounds produced a dose-dependent depression of the concentration-
response curves [32]. 
3.2.2. Histamine H2 Receptor Antagonist Activity on the Isolated Guinea Pig Right Atrium 
The investigations for H2 receptor antagonism followed the procedure described by Black et al. [33] 
with minor modifications. In brief, male guinea pigs (350–400 g) were killed by a blow on the head and 
exsanguinated. Right atria were rapidly removed, attached to a tissue holder in an organ bath (32.5 °C) 
containing 20 mL of Krebs-Henseleit solution, containing [mM] NaCl 118, NaHCO3 25, KCl 4.7, KH2PO4 
1.2, CaCl2 2.5, MgSO4 1.6, glucose 6.2, gassed with 95% O2/5% CO2, bath temperature 32.5 °C. The 
antagonistic potency was determined from isometrically recorded cumulative concentration-response 
curves using histamine dihydrochloride (0.1–10 µM) as the reference substance [34]. The incubation 
period was generally 30 min for the antagonists. For pharmacological screening, 2–5 experiments were 
carried out for each antagonist at one or two concentrations (Table 1) and pKB values were calculated 
as above. 
4. Conclusions 
Starting from lead compound 1 according to the working hypothesis that the incorporation of a 
mepyramine-like structure linked via a six-membered-spacer with a cyanoguanidine instead of urea as 
a polar group and combined with a tiotidine-like partial structure, significantly improved H1R 
antagonist activity and restored pronounced H2R antagonism. However, the affinity at both receptors 
should be further increased with respect to the development of combined H1R/H2R antihistamine as 
potential pharmacotherapeutic agents. Generally, pharmacological hybrids harbour the potential of 
improving the pharmacokinetic properties compared to single drugs with different half lives. Further 
progress in structural optimization seems possible through selection of other H1R and H2R 
pharmacophoric moieties known to possess histamine receptor subtype affinity. Nevertheless, this has 
to be proven experimentally, because the mutual affinity-conferring or -enhancing contribution of the 
respective substructures cannot be predicted on the basis of the structure-activity relationships 
available so far. Different routes of administration are conceivable, for example, topical applications of 
combined H1R/H2R antagonists in dermatology or systemic administration for premedication in 
anaesthesia and surgery or for the prevention of hypersensitivity reactions to drug treatment, e.g., in 
cancer chemotherapy. This has to be taken into consideration with respect to optimization of the 
physicochemical properties. 
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